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Background:  The  Polio  Endgame  strategy  includes  phased  withdrawal  of  oral poliovirus  vaccines  (OPV)
coordinated  with  introduction  of  inactivated  poliovirus  vaccine  (IPV) to  ensure  population  immunity.
The  impact  of IPV introduction  into  a primary  OPV  series  of immunizations  in a developing  country  is
uncertain.
Methods:  Between  May  2011  and  November  2012,  we enrolled  700  Bangladeshi  infant-mother  dyads
from  Dhaka  slums  into  an open-label  randomized  controlled  trial to  test  whether  substituting  an  injected
IPV  dose  for  the  standard  Expanded  Program  on Immunization  (EPI)  fourth  tOPV  dose  at infant  age  39
weeks  would  reduce  fecal  shedding  and  enhance  systemic  immunity.  The  primary  endpoint  was  mucosal
immunity  to  poliovirus  at age  one  year,  measured  by  fecal  excretion  of  any  Sabin  virus  at ﬁve time  points
up  to 25  days  post-52  week  tOPV  challenge,  analyzed  by  the  intention  to treat  principle.
Findings: We  randomized  350  families  to  the  tOPV  and  IPV  vaccination  arms.  Neither  study  arm  resulted
in  superior  intestinal  protection  at 52 weeks  measured  by  the  prevalence  of infants  shedding  any  of three
poliovirus  serotypes,  but  the  IPV  dose  induced  signiﬁcantly  higher  seroprevalence  and  seroconversion
rates.  This  result  was  identical  for poliovirus  detection  by cell  culture  or RT-qPCR.  The  non-signiﬁcant
estimated  culture-based  shedding  risk  difference  was  −3% favoring  IPV,  and  the two  vaccination  sched-
ules  were  inferred  to  be  equivalent  within  a 95%  conﬁdence  margin  of −10% to +4%.  Results  for  shedding
analyses  stratiﬁed  by poliovirus  type  were  similar.
Conclusions:  Neither  of  the  vaccination  regimens  is  superior  to the  other  in  enhancing  intestinal  immunity
as  measured  by  poliovirus  shedding  at 52 weeks  of age  and  the  IPV  regimen  provides  similar  intestinal
immunity  to  the  four  tOPV  series,  although  the  IPV  regimen  strongly  enhances  humoral  immunity.  The
IPV-modiﬁed  regimen  may  be  considered  for vaccination  programs  without  loss  of intestinal  protection.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. IntroductionGlobal eradication of virulent poliovirus appears tantalizingly
lose as measured by the total incidence of polio cases per year,
∗ Corresponding author. Tel.: +1 434 924 5621; fax: +1 434 924 0075.
E-mail address: wap3g@virginia.edu (W.A. Petri Jr.).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.046
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article ubut challenges remain in the pursuit of this public health land-
mark. Oral poliovirus vaccine (OPV) provides excellent intestinal
immunity and is highly effective at reducing viral fecal-oral trans-
mission but contains live attenuated poliovirus, which can result in
vaccine-associated paralytic poliomyelitis and reversion to a vir-
ulent circulating vaccine-derived strain. To eliminate that risk, a
global switch to an inactivated poliovirus vaccine will be neces-
sary. Injected inactivated poliovirus vaccine (IPV) induces excellent
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ystemic immunity and does not revert to neurovirulence, but has
 complex effect on intestinal immunity. IPV-only regimens are
pparently inferior as measured by fecal transmission after chal-
enge, but may  depend on whether IPV is administered subsequent
o doses of OPV [1–5]. Since a single coordinated global transi-
ion to solely administering inactivated vaccine is infeasible, and
ass campaigns need repetition, primary vaccination schedules
hat blend doses of OPV with IPV will be necessary during the transi-
ion period. The optimal schedule to maintain individual immunity
hile minimizing transmission of active poliovirus is unknown and
s likely to vary by region. Very recently in 2015, the Bangladesh
overnment announced that it would incorporate an IPV dose into
he existing four dose Expanded Program on Immunization (EPI)
chedule and hence data on the effects of these substitutions will
e critical for public health decision-makers.
We designed a randomized clinical trial to test the intestinal
mmune response and immunogenicity of a modiﬁed Bangladesh
xpanded Program on Immunization (EPI) vaccination regimen
ith injected IPV substituted for the fourth trivalent OPV (tOPV)
ose, administered at 39 weeks of age in this trial. Based on previ-
us studies that suggested IPV can enhance intestinal immunity and
educe poliovirus transmission by fecal shedding, we hypothesized
hat infants receiving the IPV dose after OPV intestinal priming
ould enjoy enhanced intestinal and humoral immunity with low-
red susceptibility to viral shedding.
. Materials and methods
.1. Study population and design
Seven hundred (700) eligible neonatal infant–mother dyads
ere enrolled into the Performance of Rotavirus and Oral Poliovirus
accines in Developing Countries (PROVIDE) study in Dhaka,
angladesh, as participants in two separate concomitant ran-
omized open-label clinical trials to study infant poliovirus and
otavirus vaccine interventions, structured in a 2 × 2 factorial
esign. The four study groups were: (1) dose 4 IPV + No Rotavirus;
2) dose 4 IPV + Rotavirus; (3) dose 4 tOPV + No Rotavirus; (4)
ose 4 tOPV + Rotavirus. The study was funded by the Bill and
elinda Gates Foundation. The study design and baseline clinical
haracteristics of the PROVIDE study cohort have been reported
6]. The poliovirus outcomes were assumed to be independent
f co-administered rotavirus vaccine in the second concurrent
rial [7]. Pregnant mothers from the Mirpur slum area of Dhaka
ere screened for eligibility and upon live birth, enrolled by
eld research assistants into the cohort. Eligibility for enrollment
equired delivery of a live infant of maximum age 7 days, absent
rank congenital abnormalities, birth defects, or irregular stool fre-
uency or consistency. Oral tOPV (GlaxoSmithKline) doses were
iven at infant age 6, 10, and 14 weeks, and either oral tOPV or
njected IPV (IMOVAX®, Sanoﬁ Pasteur) at 39 weeks. The govern-
ent EPI schedule for poliovirus vaccination at the time of the trial
esign in 2010 was 6, 10, 14, and 38 weeks. The fourth tOPV dose
as administered at 39 weeks in this trial but was within the pre-
erred vaccination window and was chosen to balance participant
nd clinic burden, safety, and science in the context of a larger pro-
ram to study the impact of environmental enteropathy on vaccine
nder-performance. The rationale for this choice is described in
ore detail in the Supplementary Appendix. Participants received
ree primary care during the study.
The study protocol was reviewed and approved by the icddr,besearch Review and Ethical Review Committees, and by Institu-
ional Review Boards at the Universities of Virginia and Vermont.
ll mothers signed an informed consent on behalf of their infant
hild before enrollment into the study and were free to withdraw atne 34 (2016) 358–366 359
will. The study was  conducted in compliance with the Declaration
of Helsinki and the Belmont Report [8]. Good Clinical Practice stan-
dards were applied throughout with monitoring of study progress
and adverse events by an independent medical monitor. Severe
adverse events were recorded for the full protocol period until the
ﬁnal day 25 fecal excretion sample at 52 weeks of age; adverse
events linked to vaccine administration were recorded for 48 h
post-vaccination. Adverse events were reported to ethics boards
or committees per local requirements.
2.2. Randomization and masking
Before enrollment, sequential study subject identiﬁcation num-
bers (SIDs) were randomized to one of four 2 × 2 treatment groups
using permuted block randomization with random block size (4
or 8). Sealed envelopes with treatment group assignment for each
SID were produced by the Data Coordinating Center and sent to the
Dhaka clinic. SIDs were assigned sequentially to each infant/mother
pair at the enrollment visit. The envelope was  opened at the
infant’s week six visit. Neither mothers nor clinic staff were masked.
The laboratories that performed the outcomes assays to detect
poliovirus in stool by cell culture (National Polio Laboratory) and
serum neutralizing antibody (Centers for Disease Control and Pre-
vention) were masked to specimen trial arm assignment.
2.3. Procedures
The poliovirus vaccine cell culture-based fecal excretion assays
were performed at the National Polio Reference Laboratory, Insti-
tute of Public Health, Government of Bangladesh as per the WHO
Polio Laboratory Manual [9,10]. Extraction of viral RNA from
stool and fecal multiplex RT-qPCR detection has been previously
described for the PROVIDE study [11,12]. Samples were tested for
serum neutralizing antibodies (SNAb) at the Centers for Disease
Control and Protection (Atlanta, Georgia, USA) using a standard
microneutralization assay for antibodies to poliovirus types 1, 2,
and 3 according to established protocols [13,14]. Each specimen
was run in triplicate in the same assay run; neutralization titers
were estimated by the Spearman-Kärber method[15] and reported
as the reciprocal of the calculated 50% endpoint. A serum sam-
ple was  considered seropositive if antibodies were present at ≥1:8
dilution, antibody titers <1:8 were seronegative.
2.4. Outcomes
The primary outcome was  the presence of any of three Sabin
poliovirus vaccine types determined by cell culture, in any of ﬁve
fecal samples collected after tOPV challenge dose at week 52, sam-
pled at day 0 (immediately pre-vaccination), and days 4, 11, 18, and
25 days post-vaccination. Secondary poliovirus shedding outcomes
were similar but stratiﬁed to each Sabin poliovirus type. These
outcomes were also assayed by direct fecal RT-qPCR detection
as conﬁrmation. A secondary RT-qPCR-based quantitative index
of total viral shedding was  tested by poliovirus type. Secondary
measures of humoral immunity were seropositivity for neutraliz-
ing antibody by serotype one week post-intervention dose at 39
weeks, and seroconversion from 18 to 40 weeks. Week 18 SNAb
titer was  adjusted for residual maternal antibody, assuming 28 days
half-life for maternally transmitted antibody measured at 6 weeks.
Failure to seroconvert was deﬁned as less than +2 change in log2
titer at week 40 if adjusted SNAb (week 18) ≤8.5 and >2.83; SNAb
(week 40) <10.5 if adjusted SNAb (week 18) >8.5 and <10.5; and
SNAb (week 40) ≤2.83 if adjusted SNAb (week 18) ≤2.83 (seroneg-
ative) [16]. Infants with log2 titer 10.5 at week 18 were excluded
from seroconversion analyses.
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.5. Statistical analysis
The trial was designed to test superiority of the substituted
PV dose in reducing the prevalence of any poliovirus shedding in
eces at week 52 compared to the standard fourth EPI tOPV dose,
nder a 2-sided test of proportions at alpha = 0.05. Absent exist-
ng region- and vaccination schedule-speciﬁc poliovirus excretion
ates during study planning, the power was estimated from pub-
ished studies [5,17–20]. Substitution of the 4th EPI tOPV dose for
PV was assumed to reduce any Sabin type shedding from 10 to 20%
o 5%. Assuming 20% participant loss to follow-up and intention-
o-treat analysis, 700 recruited infants gave >80% power to detect
uperiority at shedding rates 11–20% in the ﬁrst arm versus 5%
n the second at alpha = 0.05. Analyses of the primary outcome
ere performed according to the intention-to-treat (ITT) princi-
le; occurrences of outcomes were compared with the use of tests
f proportion and 95% conﬁdence intervals by the Wilson method
21] for one group proportions or the Newcombe hybrid score for
ifferences in proportions [22]. A per protocol (PP) sub-group anal-
sis was pre-speciﬁed for the primary and secondary outcomes to
ssess possible retention bias. This group received the correct num-
er doses of vaccine at the correct ages as described in the protocol.
ost-hoc, after review of missing data patterns, a second analy-
is sub-group was deﬁned, Received Protocol Dose (RPD). These
nfants received correct doses but one or more outside the preferred
PI schedule. Further details are given in Supplementary Appendix.
uring the post-week 52 tOPV challenge, some infants missed one
r more fecal sampling visits, or did not produce a stool specimen.
ll primary analyses of fecal data assumed missing samples would
ave tested negative, resulting in an under-estimated prevalence
f poliovirus shedding and a lower bound for true shedding propor-
ions. Sensitivity of the trial analysis results to these assumptions
as tested using an imputation model to predict missing shed-
ing data points (Zhang D. et al., manuscript in preparation, details
n Supplementary Appendix). The ITT, PP, and RPD results were
ompared with the corresponding complete data sets generated by
mputation. A quantitative shedding index was calculated for each
nfant for each poliovirus type as described previously [12]. The
ifference in geometric means of the shedding index between the
wo arms was assessed by t-test. The incidence of adverse events
able 1
linical characteristics of the PROVIDE Poliovirus Trial infant participants at study enrollm
IPV arm (N
Age (days) 4.9 ± 1.7
Female gender (%) 176 (50.3) 
Weight (kg) 2.8 ± 0.4
Length (cm) 48.7 ± 1.7
Infant weight for age Z score (WAZ) −1.3 ± 0.8
Infant length for age Z score (LAZ) −0.9 ± 0.9
Infant stunted at enrollment (%) 29 (8.2) 
Infant gestational age ≤36 weeks (%)† 66 (34.7) 
Breastfed at birth (%) 330 (94.3) 
Home  birth (%) 89 (25.4) 
Infant BCG administered at birth (%) 8 (2.3) 
Maternal age at delivery (years) 24.7 ± 4.8
Mother illiterate (%) 102 (29.1) 
Mother homemaker (%) 304 (86.9) 
Total  household members 5.2 ± 2.2
Number of children under 5 years of age in household 0.3 ± 0.5
Total  monthly income (Taka in thousands)§ 12.6 ± 8.7
Piped  municipal water source (%) 344 (98.3) 
Toilet, septic tank (%) 180 (51.4) 
Dwelling size equals 1 room (%) 254 (72.6) 
* Continuous variables are summarized as mean ± SD, categorical variables as number 
hose  in tOPV arm received the EPI standard oral trivalent vaccine dose.
† Infant gestational age was measured on a subset of 190 infants in the IPV arm and 191
ubowitz–Ballard assessment scale (Ballard JL, Novak KK, Driver M.  A simpliﬁed score fo
§ 1 USD approximately equaled 80 Bangladesh Taka during the study period.ne 34 (2016) 358–366
was compared with the use of Fisher’s exact test. All statistical
analyses were conducted at the Data Coordinating Center using
R version 3.1 [23]. This trial is registered with ClinicalTrials.gov,
number NCT01289782.
3. Results
We  screened 1048 mother-infant dyads for eligibility result-
ing in a target enrollment of 700 families, enrolled from May  22,
2011 to November 6, 2012, with 350 randomized to each trial arm.
At enrollment the infants were on average 5 days old (range 0–7
days), predominantly born outside the home (75%), into a single-
room dwelling family (73%), with only 50% of families having a
toilet or septic tank, and attendant economic insecurity, Table 1.
The infants were moderately-to-severely undernourished (mean
WHO  LAZ = −0.9; 10% stunted with LAZ <−2). Of these, 606 infants
(86.6%) received the week 52 tOPV challenge dose (307 tOPV, 299
IPV arm) but a further two withdrew during the series (N = 604,
CONSORT Diagram Fig. 1). Missed visits and specimens resulted
in 493/606 (81.4%) infants with complete data for 5 fecal speci-
mens. Some 481/700 (68.7%) of infants met  the stricter PP group
criteria of perfect vaccination protocol adherence while 598/700
(85.4%) received the correct doses in the RPD group (Supplemen-
tary Appendix). There was no evidence of differential missing data
by trial arm measured by number of infants with complete week
52 shedding data (N = 244 vs 249, p = 0.6) or infants missing all ﬁve
time points (N = 51 vs 43, p = 0.3).
There were 89 severe adverse events (SAEs) in the trial up
to the last day 25 fecal sampling visit after week 52, ﬁve of
which were deaths (mortality rate 5/700 = 0.7%), Supplementary
Appendix Table S3. Most of the remaining SAEs were for diarrheal
illness. Only a single SAE of hospitalization for diarrheal illness was
coded as possibly attributable to vaccination, but this occurred at 24
weeks of age. The observed rates for mortality and morbidity were
expected in this population. There were no differences in the SAE
counts between arms (death: 2/350 vs 3/350, Fisher Exact p = 1.0;
total SAEs: 46 vs 43, exact p = 0.8), or in the vaccination-related
adverse event (AE) counts (total AEs: 9 vs 15, exact p = 0.3).
Substitution of the fourth EPI tOPV dose for IPV, administered at
39 weeks of age, did not result in superior intestinal protection from
ent*.
 = 350) tOPV arm (N = 350) P-value
 5.0 ± 1.7 0.49
156 (44.6) 0.15
2.8 ± 0.4 0.60
 48.7 ± 1.8 0.80
 −1.3 ± 0.9 0.38
 −0.9 ± 0.9 0.84
38 (10.9) 0.30
57 (29.8) 0.36
332 (94.9) 0.86
92 (26.3) 0.86
8 (2.3) 1.0
 24.6 ± 4.5 0.62
100 (28.6) 0.93
297 (84.9) 0.51
 5.2 ± 2.3 0.83
 0.3 ± 0.5 1.0
 13.0 ± 10.0 0.56
334 (95.4) 0.05
187 (53.4) 0.65
253 (72.3) >0.99
(%). Infants in the IPV arm received an injected dose of IPV at 39 weeks of age while
 in the tOPV arm to distinguish fetal growth restriction from prematurity using the
r assessment of fetal maturation of newly born infants. J Pediatr 1979;95:769–74.).
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Week 39 
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dose 1 
ovirus
s
b
a
c
r
m
t
lFig. 1. The PROVIDE poli
hedding at 52 weeks of age for either vaccine regimen, measured
y the prevalence of infants shedding any of 3 poliovirus serotypes
t any of 5 time points (0, 4, 11, 18, or 25 days) after 52 week tOPV
hallenge, ITT analysis, Table 2 (2-sided test). The non-signiﬁcant
isk difference was −3% (favors IPV) with an inferred equivalence
argin of −10%, +4%(95% CI) for cell culture assay and an all type
otal fecal shedding rate of 29.7%.
Secondary analyses of individual serotype fecal shedding simi-
arly showed no signiﬁcant differences for IPV compared to tOPV, trial CONSORT diagram.
Fig. 2. The PP and RPD sub-group analyses were also consistent
with the ITT analysis for the primary and secondary shedding end-
points by serotype, hence the trial result and estimated effect sizes
are insensitive to missing data or biases resulting from ITT anal-
ysis strategy. These results were not biased by missing data since
inferences were the same for sub-group analyses using only infants
with complete ﬁve time point data, or using imputation-augmented
data, Table 2. Both complete shedding and imputation results were
consistent in estimating total shedding prevalence at 35% with a
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Table  2
Poliovirus trial primary endpoint results by trial arm.
IPV
N
tOPV
N
IPV
Prev (%)
tOPV
Prev (%)
Risk Difference
(95% CI)
Relative Risk
(95% CI)
P value
Cell culture:
Intention to treat 99/350 109/350 28.3 31.1 −2.9%
(−9.6, 3.9)
0.91
(0.72, 1.14)
0.4
Received protocol dose 98/296 108/302 33.1 35.8 −2.7%
(−10.2, 4.9)
0.93
(0.74, 1.15)
0.5
Per  protocol 75/236 87/245 31.8 35.5 −3.7%
(−12.1, 4.7)
0.89
(0.69, 1.15)
0.4
Cell  culture: infants with complete shedding data*
Intention to treat 86/244 89/249 35.2 35.7 −0.5%
(−8.9, 7.9)
0.99
(0.78, 1.25)
0.9
Received protocol dose 85/242 88/245 35.1 35.9 −0.8%
(−9.2, 7.7)
0.98
(0.77, 1.24)
0.6
Per  protocol 66/198 72/201 33.3 35.8 −2.5%
(−11.7, 6.8)
0.93
(0.71, 1.22)
0.9
Cell  culture: imputed data§
Intention to treat N/A N/A 34.8 36.7 −1.9%
(−9.6, 5.8)
0.95
(0.84, 1.06)
0.6
Received protocol dose N/A N/A 34.5 36.9 −2.4%
(−10.2, 5.4)
0.94
(0.85, 1.02)
0.6
Per  protocol N/A N/A 33.3 36.4 −3.1%
(−11.8, 5.6)
0.91
(0.82, 1.01)
0.5
Fecal  RT-PCR:
Intention to treat 145/350 141/350 41.4 40.3 1.1%
(−6.1, 8.4)
1.03
(0.86,1.23)
0.8
Received protocol dose 144/296 140/302 48.6 46.4 2.3%
(−5.7, 10.1)
1.05
(0.89, 1.24)
0.6
Per  protocol 112/236 114/245 47.5 46.5 0.9%
(−7.9, 9.8)
1.02
(0.84, 1.23)
0.8
The endpoint was the presence of any poliovirus Sabin type in any of the 5 fecal samples taken at 52 weeks of age, measured as the prevalence among infants in each arm
(Prev%).  Results are shown for the presence of poliovirus detected by cell line culture and direct RT-PCR assays.
* These results are for analysis of the subset of each study group who had complete ﬁve time point shedding data and therefore are less likely to be biased by assumptions
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tbout  missing data.
§ These results are for analysis of each study group with missing fecal data imput
herefore discrete counts by arm are not applicable.
on-signiﬁcant risk difference in the range −0.5% to −3% and a 95%
I in the approximate range of −10% to +8%. Repeating the same
nalyses using fecal RT-PCR-based detection resulted in identical
onclusions, albeit at higher shedding rates, approx. 40% (ITT) or
-15.0 -10.0 
Per protocol
Received protocol dose
Intention to treat
Per protocol
Received protocol dose
Intention to treat
Per protocol
Received protocol dose
Intention to treat
Per protocol
Received protocol dose
Intention to treat
29/236
40/296
40/350
19/236
22/296
22/350
50/236
66/296
67/350
75/236
98/296
99/350
 29/245
 34/302
 35/350
 25/245
 32/302
 33/350
 59/245
 72/302
 72/350
 87/245
108/302
109/350
Any Serotype
Serotype S1
Serotype S2
Serotype S3
IPV tOPV
ig. 2. Poliovirus fecal excretion results at 52 weeks of age. Numerator counts are the
ost-tOPV challenge over the denominator total infants included in the analysis. For eac
nd  received protocol dose sub-group analyses. Any serotype refers to shedding of any of
ized  proportional to the precision of the estimates. Two-sided bars delineate the 95% CI.
he  IPV arm versus the tOPV arm.e prevalences and risk statistics are computed as means of 1000 imputed data sets,
47% (PP or RPD), Table 2. We  tested whether the total amount of
virus shed over the 25 day period differed between trial arms as
measured by our shedding index. The mean log(shedding index)
did not differ between the arms for infants who shed poliovirus
-5.0 0.0 5.0 10.0
Risk Difference(%)
 0.5 [  -5.4 , 6.4 ]
 2.3 [  -3.1 , 7.6 ]
 1.4 [  -3.2 , 6.1 ]
-2.1 [  -7.4 , 3.1 ]
-3.2 [  -7.8 , 1.5 ]
-3.1 [  -7.2 , 0.9 ]
-2.9 [ -10.3 , 4.6 ]
-1.5 [  -8.3 , 5.2 ]
-1.4 [  -7.3 , 4.5 ]
-3.7 [ -12.1 , 4.7 ]
-2.7 [ -10.2 , 4.9 ]
-2.9 [  -9.6 , 3.9 ]
Risk Difference [95% CI]
 number of infants excreting the poliovirus serotype at any of the 5 time points
h serotype results are shown for intention-to-treat primary analysis, per protocol,
 the 3 serotypes. Points designating the location of the estimated risk difference are
 Risk differences are shown as fractions. Negative (−) values imply less shedding in
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hedding at each time point was estimated using all available non-missing data po
omplete ﬁve time data.
ype 1 (p = 0.5), 2 (p = 0.2), or 3 (p = 0.1). Shedding infants predomi-
antly shed on day 4 and 11, Fig. 3. The peak shedding rate was day
(any: 180/578, 31%), then day 11(any: 56/560, 10%) for all three
oliovirus types. Omission of the day 0, 18, and 25 assays would
ave missed only 9/208 (4.3%) infants shedding any poliovirus. Only
ight infants shed on day 0 prior to tOPV challenge (8/208, 3.8%).
The IPV vaccination resulted in lower seronegativity rates for
ll three types compared to tOPV, Fig. 4. Seronegativity in the tOPV
rm was 5.3% vs 0.3% in the IPV arm for type 1 (ITT, p = 0.002, Fisher
xact) and 5.9% vs 1.4% for type 3 (p = 0.01, Fisher exact). Type 2
eronegativity also reduced from 1.0% to 0% (p = 0.25, Fisher Exact,
tatistical non-signiﬁcance due to minute number of seronegative
nfants). Infants in the IPV arm enjoyed much higher rates of sero-
onversion of all three antibody types from week 18 to week 40
ith 95–96% in the IPV arm, while the tOPV arm ranged from
9%(type 3) to 63%(type 1) and 71%(type 2) (all p < 0.0001). We
ested the SNAb week 40 measures of seropositivity and serocon-
ersion as predictive correlates of future week 52 shedding, Table 3.
nfants who achieved seropositivity or had seroconverted between
eek 18 and week 40 were less likely to shed at week 52 thanhose that had not for all serotypes. Comparing the IPV to tOPV
rm, while the absolute numbers varied, the percentages of infants
ho shed at week 52 were the same whether measured by their
ositive SNAb status as positivity or conversion, with percentages shown for the combined data for all infants in both trial arms. The prevalence of
he total prevalence of shedding by serotype was estimated using only infants with
approximately 24%, 10%, and 13% for S1, S2, S3, respectively.
For infants who  had negative SNAb measures at week 40 (were
seronegative or had not seroconverted), seronegativity was  the
better correlate of week 52 shedding, albeit with small absolute
numbers in the case of IPV-vaccinated infants. In other words, for
infants who  were seropositive or had seroconverted, there was lit-
tle difference in the predictive value of the two  humoral measures.
It is important to note that 53%, 59%, and 28% of infants achieved the
maximum possible log2 titer of 10.5 at week 18 for types 1, 2, and 3,
respectively, and were censored from the seroconversion analysis
but included in the seropositivity analysis. Inferences were similar
with all infants included that had at least one non-missing week 52
stool specimen, assuming missing specimens were negative.
4. Discussion
Global elimination of wild type poliovirus will require contin-
ued use of OPV to effectively disrupt transmission of live virus,
while subsequent eradication of all circulating Sabin virus strains
will necessitate a managed global transition to IPV. This transition
will require interim regimens that blend both types of vaccine and
requires rigorous data on speciﬁc pragmatic substitutions. With
the impending withdrawal of OPV2 in April 2016, the Bangladesh
EPI announced changes to their national immunization program
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Seronegative S1
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Seronegative S3
Non-seroconversion S1
Non-seroconversion S2
Non-seroconversion S3
IPV tOPV Risk Difference [95% CI]
Fig. 4. Plot of serum neutralizing antibody (SNAb) secondary outcomes measured in serum from age week 40 infants after the trial IPV vs tOPV intervention at week 39. The
outcomes are deﬁned to focus on possible vaccine failure. Seronegative infants had no detectable SNAb at week 40. Seroconversion failure are infants who did not seroconvert
between week 18 (post tOPV dose 2) and week 40, adjusted for residual maternal antibody, as described in the text. All of the differences are statistically signiﬁcant in favor
of  IPV with the exception of seronegativity (SNA Failure) in type 2, due to the very low numbers of failures. Points designating the location of the estimated risk difference
are  sized proportional to the precision of the estimates. Risk differences are shown as fractions. Negative (−) values imply lower seronegativity or non-seroconversion in the
IPV  arm versus the tOPV arm.
Table 3
Comparison of infant week 40 serum neutralizing antibody (SNAb) humoral measures as correlates of future poliovirus shedding at 52 weeks of age, by virus type.
Study arm Type Week 40 serum
neutralizing antibody
measure*
Infants N shed/total (%)
with +ve SNAb
measure at Week 40
Infants N shed/total (%)
with −ve SNAb
measure at Week 40
P-value †
Both S1 Seropositivity 110/474 (23%) 7/13 (54%) 0.02
S2  Seropositivity 45/484 (9%) 2/3 (67%) 0.03
S3  Seropositivity 57/467 (12%) 7/20 (35%) 0.01
S1  Seroconversion 65/276 (24%) 24/76 (32%) 0.18
S2  Seroconversion 27/279 (10%) 9/58 (16%) 0.24
S3  Seroconversion 38/264 (14%) 18/101 (18%) 0.42
IPV  S1 Seropositivity 57/240 (24%) 1/1 (100%) 0.24
S2  Seropositivity 20/241 (8%) 0/0 (N/A%) N/A
S3  Seropositivity 32/238 (13%) 1/3 (33%) 0.36
S1  Seroconversion 41/169 (24%) 4/9 (44%) 0.23
S2  Seroconversion 13/155 (8%) 2/8 (25%) 0.16
S3  Seroconversion 28/181 (15%) 3/11 (27%) 0.39
tOPV  S1 Seropositivity 53/234 (23%) 6/12 (50%) 0.04
S2  Seropositivity 25/243 (10%) 2/3 (67%) 0.03
S3  Seropositivity 25/229 (11%) 6/17 (35%) 0.01
S1  Seroconversion 24/107 (22%) 20/67 (30%) 0.29
S2  Seroconversion 14/124 (11%) 7/50 (14%) 0.61
S3  Seroconversion 10/83 (12%) 15/90 (17%) 0.52
* Seropositivity and Seroconversion at week 40 refer to the SNAb titer and change in SNAb titer from week 18 to week 40, respectively, as described in Procedures. The
counts  are restricted to those 493 infants with ﬁve complete week 52 shedding stool specimens. The % measures the predictive value of the week 40 SNAb measure (either
+ve  or −ve) to predict future shedding at week 52. A +ve SNAb measure refers to seropositivity or serconversion at week 40; the corresponding −ve measures are seronegative
at  week 40 and failed to seroconvert.
† P-value refers to exact test for difference in proportion of infants between the +ve and −ve week 40 SNAb groups, i.e. a difference in predictive value of this measure.
 Vacci
i
t
w
a
p
s
t
−
f
t
t
p
w
r
a
t
w
3
o
i
t
b
r
m
i
[
i
v
m
f
t
U
s
r
n
t
i
I
i
i
e
t
[
s
e
t
f
4
t
I
i
a
l
r
t
w
i
c
o
l
t
iJ.C. Mychaleckyj et al. /
n March 2015, including addition of an IPV dose which will con-
ain the sole administered type 2 vaccine in this new schedule. This
ork is timely in assessing the effects of the transition on shedding.
Prior work has suggested that IPV may  be at least as effective
s OPV in reducing viral excretion when administered to a child
rimed by prior OPV vaccination [1,2]. We  found that neither of the
chedules tested in this study was superior to other, and estimated
hat they were equivalent to within a shedding rate difference of
10% (favors IPV) to +4% (favors tOPV). This equivalence was rein-
orced by direct fecal RT-PCR assay and quantitative comparison of
he total shedding index between the trial arms at 52 weeks. Fur-
hermore, for the more neurovirulent and recent wild type 1 and 3
oliovirus strains, the IPV dose boosted the number of infants who
ere seropositive for type 1 by 5% compared to 4 OPV doses thereby
educing the fraction who were seronegative to about 0.3%; and by
bout 4.5% for type 3, reducing the seronegatives to 1%. Similarly,
he IPV dose increased the percentage who seroconverted between
eek 18 and 40 by about 35% and 46% respectively for type 1 and
. This suggests that IPV can be substituted into the fourth dose
f the EPI program in Bangladesh without relative diminution of
ntestinal immunity while boosting immunogenicity.
Results for our modiﬁed EPI schedule extend previous work that
ested combinations of OPV and IPV. An IPV dose has been shown to
oost antibody response rates of seropositivity and seroconversion
elative to OPV after prior OPV vaccinations [19,24–26] Further-
ore, mixed IPV/OPV schedules seem to have similar intestinal
mmunity to equivalent dose OPV-only, and better than IPV alone
4,19,25]. Two very recent studies in India have shown that admin-
stering a single dose of IPV in older children post-scheduled
accination improves both humoral and intestinal immunity and
ay  help to close the waning immunity gap [27,28]. Jafari et al.
ound that IPV was superior to bOPV in reducing any shedding in
hree cohorts of children ages 6–11months, and 5, and 10 years [27].
nlike our results, the 6–11month cohort, of most relevance to this
tudy, also saw signiﬁcant reduction of type 1 and type 3 shedding
elative to controls and bOPV groups. The exact reason for the sig-
iﬁcant improvement in intestinal immunity using IPV compared
o OPV in contrast to our study is unclear but may  be related to local
mmunogenicity factors or previous dosing. Our results suggest that
PV can be substituted for tOPV without compromising intestinal
mmunity, but that IPV does not additionally improve intestinal
mmunity beyond OPV. Mass campaign interventions have been
ffective in regional elimination of poliovirus, but require repeti-
ion and can subtract from limited primary healthcare resources
29].
We  found that either humoral measure, SNAb seropositivity or
eroconversion at week 40, predicted future shedding at week 52
qually well. We  also found that the future risk of shedding is
he same after 3 tOPV doses + IPV versus the four tOPV dose arm
or infants that were seropositive or had seroconverted at week
0. The best discriminating predictor of future shedding for the
OPV arm infants was seropositivity versus seronegativity. For the
PV arm, the small numbers of seronegative or non-seroconverted
nfants makes comparisons difﬁcult, but neither humoral measure
pproached being a perfect correlate of future shedding risk.
Our trial has limitations. We  recruited only from a single popu-
ation with economic and sanitary deprivation. The tested vaccine
esponses could have been confounded by passive vaccination
hrough community contact although the high excretion rate at
eek 52 suggests that this is likely to be a small effect if present. We
nvestigated trivalent OPV and not selective bi- or monovalent vac-
ines that target less immunogenic serotypes. We  did not measure
ropharyngeal excretion although in this urban slum population
acking sanitation, the predominant mode of transmission is likely
o be fecal-oral versus oral-oral and hence oropharyngeal immunity
s a less important component in limiting viral transmission. This isne 34 (2016) 358–366 365
supported by prior studies showing that oropharyngeal shedding
did not substantially contribute to wild poliovirus transmission in
older children in Bihar, India [30], and that type 1 oropharyngeal
shedding was comparatively low compared to fecal shedding for
both IPV and OPV schedules [31]. Finally, while the responses were
measured up to one year of age, potential long-term changes or
waning immunity over time were not addressed.
In summary, our study shows that incorporation of IPV into pri-
mary vaccination schedules is possible while maintaining existing
intestinal immunity to limit fecal transmission, yet giving children
extra seroprotection from IPV at an earlier age, reducing the need
for supplementation later.
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